Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ohtsuki

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
International Immunology|April 1, 2000
A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicityK Ichikawa, H Yoshida-Kato, M Ohtsuki, et al.
The Journal of International Medical Research|August 19, 2007
Efficacy of atorvastatin therapy in ischaemic heart disease - effects on oxidized low-density lipoprotein and adiponectinK Miyagishima, S Hiramitsu, S Kato, et al.
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology|December 17, 1998
Enzymes related to catecholamine biosynthesis in Tetrahymena pyriformis. Presence of GTP cyclohydrolase IT Nomura, M Tazawa, M Ohtsuki, et al.
The British Journal of Dermatology|June 11, 2017
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasisK A Papp, H Bachelez, A Blauvelt, et al.
Journal of Medicinal Chemistry|August 24, 2000
Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanolsM Kiuchi, K Adachi, T Kohara, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 13, 2017
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasisA Blauvelt, K A Papp, H Sofen, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
The British Journal of Dermatology|October 10, 2017
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)K A Papp, C L Leonardi, A Blauvelt, et al.
The British Journal of Dermatology|September 30, 2019
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trialsN Katoh, Y Kataoka, H Saeki, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
International Immunology|April 1, 2000
A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicityK Ichikawa, H Yoshida-Kato, M Ohtsuki, et al.
The Journal of International Medical Research|August 19, 2007
Efficacy of atorvastatin therapy in ischaemic heart disease - effects on oxidized low-density lipoprotein and adiponectinK Miyagishima, S Hiramitsu, S Kato, et al.
The British Journal of Dermatology|June 22, 2021
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-upK A Papp, M G Lebwohl, L Puig, et al.
Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology|December 17, 1998
Enzymes related to catecholamine biosynthesis in Tetrahymena pyriformis. Presence of GTP cyclohydrolase IT Nomura, M Tazawa, M Ohtsuki, et al.
The British Journal of Dermatology|June 11, 2017
Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasisK A Papp, H Bachelez, A Blauvelt, et al.
Journal of Medicinal Chemistry|August 24, 2000
Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanolsM Kiuchi, K Adachi, T Kohara, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 13, 2017
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasisA Blauvelt, K A Papp, H Sofen, et al.
The British Journal of Dermatology|June 21, 2019
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeksK Reich, R B Warren, L Iversen, et al.
The British Journal of Dermatology|October 10, 2017
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)K A Papp, C L Leonardi, A Blauvelt, et al.
The British Journal of Dermatology|September 30, 2019
Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trialsN Katoh, Y Kataoka, H Saeki, et al.
Pageof 13